000			02970nam a22004217a 4500
008			240807s20242024 xxu||||| |||| 00| 0 eng d
022			_a2213-1779
024			_aS2213-1779(24)00338-X [pii]
040			_aOvid MEDLINE(R)
099			_a38878007
245			_aCost-Effectiveness of Sotagliflozin in SOLOIST-WHF.
251			_aJACC Heart Failure. 2024 Jun 01
252			_aJACC Heart Fail. 2024 Jun 01
253			_aJACC. Heart failure
260			_c2024
260			_fFY2024
260			_p2024 Jun 01
265			_saheadofprint
265			_tPublisher
266			_d2024-08-07
266			_z2024/06/15 10:32
520			_aBACKGROUND: The efficacy of sotagliflozin in patients with diabetes and recent worsening of heart failure was shown in the SOLOIST-WHF trial. However, the cost-effectiveness of sotagliflozin in these patients has not been previously investigated.
520			_aCONCLUSIONS: In patients with diabetes and recent worsening of heart failure, sotagliflozin is cost-effective in the U.S. using commonly accepted willingness-to-pay thresholds. (Effect of Sotagliflozin on Cardiovascular Events in Participants With Type 2 Diabetes Post Worsening Heart Failure [SOLOIST-WHF]; NCT03521934). Copyright © 2024 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
520			_aMETHODS: Based on SOLOIST-WHF trial data (N = 1,222), we constructed a Markov model to estimate the lifetime impact of sotagliflozin from a U.S. health care sector perspective. Cost data were sourced from the National Inpatient Sample. Life expectancy was modeled from census data and modified by the mortality rate in SOLOIST-WHF. Fatal and nonfatal event rates were carried forward from the trial data. Utility was assessed from the published reports.
520			_aOBJECTIVES: The authors sought to determine the cost-effectiveness of sotagliflozin in patients with diabetes and recent worsening of heart failure.
520			_aRESULTS: Lifetime quality-adjusted life-years (QALYs) were 4.43 and 4.04 in the sotagliflozin and placebo groups, respectively, and lifetime costs were _220,113 and _188,198 in the sotagliflozin and placebo groups, respectively. The point estimate incremental cost-effectiveness ratio was _81,823 per QALY gained. The probability of being cost-effective was 3.6%, 67.5%, and 89.4% at willingness-to-pay thresholds of _50,000, _100,000, and _150,000, respectively, per QALY gained.
546			_aEnglish
650			_aIN PROCESS -- NOT YET INDEXED
650			_zAutomated
651			_aMedStar Health Research Institute
657			_aJournal Article
700			_aDolman, Sarahfaye _bMHRI
700			_aKolm, Paul _bMHRI
700			_aWeintraub, William S _bMHRI
790			_aWeintraub WS, Kolm P, Dolman S, Alva M, Bhatt DL, Zhang Z
856			_uhttps://dx.doi.org/10.1016/j.jchf.2024.04.018 _zhttps://dx.doi.org/10.1016/j.jchf.2024.04.018
942			_cART _dArticle
999			_c14383 _d14383